HedgePath Pharmaceuticals Announces Positive FDA Feedback from FDA Type-C Meeting and Files Pre-NDA Meeting Request
FDA has confirmed HPPI's clinical and regulatory pathway for SUBA BCCNS and provided further guidance for anticipated NDA submission PR ...
